Neuromuscular Blockade Clinical Trial
Official title:
Deep Neuromuscular Blockade During Laparoscopic Surgery in Pediatric Patient and the Impact of the Depth of the Blockade on the Surgery Conditions, Perioperative Complications and Surgeon Satisfaction
This randomized study prospectively evaluates our experience with administration of cisatracurium and rocuronium antagonized by sugammadex and evaluates the effects of various depths of neuromuscular blockage on providing optimal surgical conditions during laparoscopy with low-pressure capnoperitoneum.
This randomized study prospectively evaluates our experience with administration of
cisatracurium and rocuronium antagonized by sugammadex and evaluates the effects of various
depths of neuromuscular blockage on providing optimal surgical conditions during laparoscopy
with low-pressure capnoperitoneum.
After meeting inclusion criteria the patients will be randomized - - use of opaque envelopes,
randomization into groups A and B in an operating theatre, study blinded for the patient (or
his/her legal guardian) and surgeon.
Group A - muscle relaxation using rocuronium followed by sugammadex reversal (in a dose
according to TOF - (train-of-four) 2-4mg/kg), depth of muscle relaxation TOF 0 PTC
(post-tetanic count) 0-1 Group B - muscle relaxation using cisatracurium followed by
decurarization (neostigmine 0.03 mg/kg and atropine 0.02 mg/kg)
Anesthesia management:
- intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol
2.0mg/kg and in Group A - rocuronium 0.6 mg/kg (1 mg/kg only in a case of a rapid
sequence induction), in Group B - cisatracurium 0.15mg/kg
- orotracheal intubation, combined anesthesia using sevoflurane - MAC (minimal alveolar
concentration) 1.0 with respect to the age of the patient
- ventilation: PCV (pressure-controlled ventilation ), PEEP (positive end-expiratory
pressure) +5 cm H2O (aqua), normocapnia, FiO2 (fraction of inspired oxygen ) 1.0 until
the intubation, afterwards 0.4 + AIR
- nasogastric tube placement
Management of neuromuscular blockade:
Group A - maintaining of deep muscular blockage - according to TOF 0, PTC 0-1, boluses of
rocuronium 0.3 mg/kg are allowed Group B - maintaining of muscular relaxation TOF 1, boluses
of cisatracurium 0.03 mg/kg are allowed Laparoscopy - capnoperitoneum pressure - 10 mmHg with
a reduction to 8 mmHg if possible
During the surgery the surgical conditions will be scored by using Surgical scoring system:
(1-2 surgeons involved):
1. Optimal conditions: there is a wide laparoscopic field, no movements or contractions
2. Good conditions: there is a wide laparoscopic field with singular movements or muscle
contractions
3. Acceptable conditions: there is a wide laparoscopic field but muscle contractions and/or
movements occur regularly. Additional neuromuscular blocking agent is required.
4. Poor conditions: the same as in grade 3 and in addition, there is a hazard of tissue
damage.
5. Extremely poor conditions: the surgeon cannot work because of weak muscle relaxation,
the patient is coughing. Additional neuromuscular blocking agent is essential.
Recovery from anesthesia:
- extubation - TOF 0.9 - using sugammadex in Group A (2-4 mg/kg according to the depth of
muscle relaxation) or decurarization in Group B (atropine 0.02 mg/kg and neostigmine
0.03mg/kg)
- after standard 2-hour monitoring in the recovery room (heart rate, blood pressure, SpO2
(oxygen saturation by pulse oximetry), level of consciousness, PONV), patients will be
observed in the intensive care unit for at least 24 hours Statistical analysis:
(provided by IBA MUNI - Institute of biostatistic and analyses by Masaryk University
Brno, Czech Republic)
- demographic parameters - age, gender, type and duration of surgery
- induction to general anesthesia - time until intubation (recognition of the capnogram
curve)
- ventilation - changes in the inspiratory pressure during capnoperitoneum, increase of
EtCO2 (end-tidal CO2)
- capnoperitoneal pressure
- surgical scoring system
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05558969 -
The Effect of Magnesium Use in Reversal of Neuromuscular Block With Sugammadex
|
N/A | |
Completed |
NCT03168308 -
Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients
|
Phase 4 | |
Not yet recruiting |
NCT03978780 -
Erector Spinae Block vs. Placebo Block Study
|
N/A | |
Completed |
NCT02892045 -
Mindray Neuromuscular Transmission Transducer
|
||
Completed |
NCT02912039 -
Electromyographic Assessment of the TetraGraph in Normal Volunteers
|
||
Completed |
NCT03427385 -
Minimum Local Anesthetic Dose for Adductor Canal Block
|
N/A | |
Completed |
NCT01450813 -
The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy
|
N/A | |
Completed |
NCT00535496 -
Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)
|
Phase 3 | |
Recruiting |
NCT05794503 -
Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex
|
Early Phase 1 | |
Not yet recruiting |
NCT05993390 -
Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04609410 -
Bleeding in Laparoscopic Liver Surgery
|
N/A | |
Terminated |
NCT03649672 -
The Validity and Tolerability of Awake Calibration of the TOF Watch SX Monitor
|
N/A | |
Completed |
NCT05474638 -
Comparison of Mechanomyographic 100 Versus 200 Hz 5 Second Tetanic Fade Ratios During Neuromuscular Block Recovery
|
N/A | |
Completed |
NCT05687253 -
Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery
|
Phase 2 | |
Completed |
NCT05120999 -
Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring
|
||
Completed |
NCT03572413 -
The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis.
|
Phase 4 | |
Completed |
NCT03608436 -
The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Early Quality of Recovery
|
Phase 4 | |
Recruiting |
NCT02930629 -
Residual Block in Postoperative Anaesthetic Care Unit
|
N/A | |
Completed |
NCT02932254 -
Magnesium Sulfate Effect Following the Reversal of Neuromuscular Blockade Induced by Rocuronium With Sugammadex
|
Phase 4 | |
Completed |
NCT01828385 -
Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex
|
Phase 4 |